论文部分内容阅读
目的探讨急性淋巴细胞白血病(acute lymphoblastic leukemia,ALL)患者FLT3(Fms-like tyrosine kinase)基因内部串联重复(internal tandem duplication,ITD)与其ASP835(D835)突变(mutation in the tyrosine kinase domain,FLT3-TKD)的发生情况及临床意义。方法采用聚合酶链反应法(polymerase chain reaction,PCR)扩增产物,采用限制性酶切产物分析法分析初诊患者基因易突变区的突变情况。结果 147例ALL患者中,11例(7.5%)存在FLT3突变。FLT3突变患者与无突变患者在年龄、性别、骨髓原始细胞计数和外周血原始细胞计数的比较均无统计学意义(均P>0.05)。T细胞型ALL(T-ALL)患者中FLT3突变的发生率为17.2%,其他类型ALL患者中FLT3突变的发生率为5.1%,差异具有非常显著的统计学意义(P<0.001)。结论 ALL患者存在FLT3突变,且T-ALL患者的FLT3突变率高于其他类型患者。
Objective To investigate the relationship between the IT tandem duplication (FLT3) and its mutation in the tyrosine kinase domain (FLT3-TKD) in patients with acute lymphoblastic leukemia (ALL) ) Of the occurrence and clinical significance. Methods The polymerase chain reaction (PCR) was used to amplify the product, and the restriction analysis of the product was used to analyze the mutation of the gene mutation region in newly diagnosed patients. Results Of the 147 ALL patients, 11 (7.5%) had FLT3 mutations. There were no significant differences in age, sex, bone marrow blast cell count and peripheral blood blast cell count between patients with and without FLT3 mutation (all P> 0.05). The incidence of FLT3 mutation was 17.2% in patients with T cell ALL and 5.1% in patients with other types of ALL. The difference was statistically significant (P <0.001). Conclusion There is FLT3 mutation in ALL patients, and the mutation rate of FLT3 in T-ALL patients is higher than other types of patients.